On September 21, Yifan Pharmaceutical and South Korea's Boryeong Pharmaceutical announced that they have reached a cooperation: Yifan Pharmaceutical has obtained general agency rights for Taisoti® in China, which is fully responsible for the marketing, channel distribution and commercial operation of this product within China, further enriching Yifan Pharmaceutical's solid tumor pipeline.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.